Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Wiley full text link Wiley Free PMC article
Full text links

Actions

Share

Review
.2017 Apr;83(4):909-922.
doi: 10.1111/bcp.13161. Epub 2016 Dec 4.

Sertraline use in the first trimester and risk of congenital anomalies: a systemic review and meta-analysis of cohort studies

Affiliations
Review

Sertraline use in the first trimester and risk of congenital anomalies: a systemic review and meta-analysis of cohort studies

Zi-Qi Shen et al. Br J Clin Pharmacol.2017 Apr.

Abstract

Aim: To perform a meta-analysis of available cohort studies on the association between sertraline use by pregnant women in the first trimester and the findings of congenital anomalies in infants.

Methods: A comprehensive search of articles published from the index date up to 31st December 2015 investigating the aforementioned associations was conducted on PubMed and Web of Science. Mesh headings used included the terms "serotonin reuptake inhibitor," "sertraline," "congenital anomalies" and "obstetrical outcome."

Results: Twelve cohort studies that involved 6 468 241 pregnant women were identified. We summarized odds ratios (ORs) and 95% confidence intervals (CIs) of congenital anomalies using the random-effects model. Pregnant women who used sertraline in the first trimester had a statistically significant increased risk of infant cardiovascular-related malformations (OR = 1.36; 95% CI = 1.06-1.74; I2 = 64.4%; n = 12) as well as atrial and/or ventricular septal defects (OR = 1.36, 95% CI = 1.06-1.76; I2 = 62.2%; n = 8). Additionally, positive but nonsignificant associations between sertraline use and congenital anomalies of the nervous system (OR = 1.39; 95% CI = 0.83-2.32; I2 = 0%; n = 5), digestive system (OR = 1.23; 95% CI = 0.76-1.98; I2 = 0%; n = 5), eye, ear, face and neck (OR = 1.08; 95% CI = 0.33-3.55; I2 = 32.1%; n = 3), urogenital system (OR = 1.03; 95% CI = 0.73-1.46; I2 = 0%; n = 5), and musculoskeletal system (OR = 0.97; 95% CI = 0.69-1.36; I2 = 0%; n = 5) were observed.

Conclusion: This meta-analysis suggested that the use of sertraline use by pregnant women in the first trimester had an increased risk of cardiovascular-related malformations as well as atrial and/or ventricular septal defects in infants. Meanwhile, nonsignificant associations between sertraline use and other congenital anomalies were found. More cohort studies are warranted to provide detailed results of other congenital anomalies.

Keywords: antidepressive agents; cohort studies; congenital anomalies; meta-analysis; pregnancy; sertraline.

© 2016 The British Pharmacological Society.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow‐chart of study selection
Figure 2
Figure 2
Forest plots of the relationship between sertraline use and risk of cardiovascular‐related malformations. Squares indicate study‐specific risk estimates (size of the square reflects the study‐specific statistical weight); horizontal lines indicate 95% confidence intervals (CIs); diamond indicates the summary odds ratio with its 95% CI. OR: odds ratio
Figure 3
Figure 3
Forest plots of the relationship between sertraline use and congenital anomalies of the nervous system, digestive system, eye, ear, face and neck, urogenital system, and musculoskeletal system. Squares indicate study‐specific risk estimates (size of the square reflects the study‐specific statistical weight); horizontal lines indicate 95% confidence intervals (CIs); diamond indicates the summary odds ratio with its 95% CI
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SP, et al. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucl Acids Res 2016; 44: D1054–D1068. - PMC - PubMed
    1. Alexander SPH, Fabbro D, Davenport AP, Kelly E, Marrion N, Peters JA, et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein‐coupled receptors. Br J Pharmacol 2015; 172: 5744–5869. - PMC - PubMed
    1. Ellfolk M, Malm H. Risks associated with in utero and lactation exposure to selective serotonin reuptake inhibitors (SSRIs). Reprod Toxicol 2010; 30: 249–260. - PubMed
    1. Braithwaite EC, Murphy SE, Ramchandani PG. Effects of prenatal depressive symptoms on maternal and infant cortisol reactivity. Arch Womens Ment Health 2016; 19: 581–590. - PMC - PubMed
    1. Davis EP, Glynn LM, Dunkel SC, Hobel C, Chicz‐Demet A, Sandman CA. Corticotropin‐releasing hormone during pregnancy is associated with infant temperament. Dev Neurosci 2005; 27: 299–305. - PubMed

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full text links
Wiley full text link Wiley Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp